Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 14, 2026

Daily Signals

2485 companies scored · 2026-10-14 run in progress: 2478 of ~5379 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-14 Cut-offs from the 2026-10-13 run
Companies scored 2485 IC ≥ 0 · market cap ≥ $100M
Median forecast +0.26% Alpha · 90D
Long–short spread +3.94% Strong Buy minus Strong Sell, mean
Median IC 0.29 Spearman · 90D
Rating changes ▲ 53 ▼ 57 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

288 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
201 GALTGALECTIN THERAPEUTICS INC Life Sciences 0.10 $390M Neutral +0.21% +0.34% ·
202 MYGNMYRIAD GENETICS INC Life Sciences 0.50 $390M Unlock rating and forecasts
203 CANFCan-Fite BioPharma Ltd. Life Sciences 0.18 $387M Unlock rating and forecasts
204 EDITEditas Medicine, Inc. Life Sciences 0.61 $376M Unlock rating and forecasts
205 RLMDRELMADA THERAPEUTICS, INC. Life Sciences 0.31 $358M Unlock rating and forecasts
206 ENTAENANTA PHARMACEUTICALS INC Life Sciences 0.46 $358M Unlock rating and forecasts
207 FENCFENNEC PHARMACEUTICALS INC. Life Sciences 0.26 $357M Unlock rating and forecasts
208 KYTXKyverna Therapeutics, Inc. Life Sciences 0.39 $357M Unlock rating and forecasts
209 EBSEmergent BioSolutions Inc. Life Sciences 0.30 $354M Unlock rating and forecasts
210 NBPNovaBridge Biosciences Life Sciences 0.59 $342M Neutral -0.10% -0.39% ·
211 CCCCC4 Therapeutics, Inc. Life Sciences 0.58 $342M Unlock rating and forecasts
212 ARCTArcturus Therapeutics Holdings Inc. Life Sciences 0.16 $342M Unlock rating and forecasts
213 TTRXTurn Therapeutics Inc. Life Sciences 0.72 $331M Unlock rating and forecasts
214 CGCCanopy Growth Corp Life Sciences 0.27 $323M Unlock rating and forecasts
215 AGENAGENUS INC Life Sciences 0.08 $313M Neutral +0.28% +0.14% ·
216 ARTVArtiva Biotherapeutics, Inc. Life Sciences 0.30 $308M Unlock rating and forecasts
217 CYPHCYPHERPUNK TECHNOLOGIES INC. Life Sciences 0.04 $306M Neutral +0.23% -0.34% ·
218 OCGNOcugen, Inc. Life Sciences 0.30 $300M Unlock rating and forecasts
219 CABACabaletta Bio, Inc. Life Sciences 0.06 $287M Unlock rating and forecasts
220 USNAUSANA HEALTH SCIENCES INC Life Sciences 0.59 $286M Unlock rating and forecasts
221 NWBONORTHWEST BIOTHERAPEUTICS INC Life Sciences 0.03 $277M Neutral -0.10% -0.29% ·
222 SRZNSurrozen, Inc./DE Life Sciences 0.00 $276M Unlock rating and forecasts
223 ELTPELITE PHARMACEUTICALS INC /NV/ Life Sciences 0.37 $275M Unlock rating and forecasts
224 VNDAVanda Pharmaceuticals Inc. Life Sciences 0.38 $260M Neutral +0.23% +0.48% ·
225 CATXPerspective Therapeutics, Inc. Life Sciences 0.23 $259M Unlock rating and forecasts
226 LABSTANDARD BIOTOOLS INC. Life Sciences 0.27 $259M Unlock rating and forecasts
227 ABEOABEONA THERAPEUTICS INC. Life Sciences 0.15 $258M Unlock rating and forecasts
228 BIOABioAge Labs, Inc. Life Sciences 0.56 $256M Unlock rating and forecasts
229 MREOMereo BioPharma Group plc Life Sciences 0.55 $256M Unlock rating and forecasts
230 RCKTROCKET PHARMACEUTICALS, INC. Life Sciences 0.35 $252M Unlock rating and forecasts
231 IPSCCentury Therapeutics, Inc. Life Sciences 0.23 $250M Unlock rating and forecasts
232 IKTInhibikase Therapeutics, Inc. Life Sciences 0.01 $246M Unlock rating and forecasts
233 SABSSAB Biotherapeutics, Inc. Life Sciences 0.27 $244M Neutral +0.23% -0.34% ·
234 LFCRLIFECORE BIOMEDICAL, INC. \DE\ Life Sciences 0.04 $243M Neutral +0.15% -0.22% ·
235 QTTBQ32 Bio Inc. Life Sciences 0.17 $240M Neutral -0.17% -0.04% ·
236 FATEFATE THERAPEUTICS INC Life Sciences 0.23 $240M Unlock rating and forecasts
237 IMRXImmuneering Corp Life Sciences 0.12 $230M Neutral +0.37% +0.11% ·
238 GLSIGreenwich LifeSciences, Inc. Life Sciences 0.21 $228M Unlock rating and forecasts
239 LXEOLexeo Therapeutics, Inc. Life Sciences 0.01 $225M Unlock rating and forecasts
240 NATRNATURES SUNSHINE PRODUCTS INC Life Sciences 0.61 $225M Neutral +0.23% -0.33% ·
241 KROSKeros Therapeutics, Inc. Life Sciences 0.19 $223M Unlock rating and forecasts
242 SIGASIGA TECHNOLOGIES INC Life Sciences 0.46 $221M Neutral +0.23% +0.21% ·
243 MGNXMACROGENICS INC Life Sciences 0.33 $218M Unlock rating and forecasts
244 ADCTADC Therapeutics SA Life Sciences 0.43 $217M Unlock rating and forecasts
245 AKBAAkebia Therapeutics, Inc. Life Sciences 0.01 $213M Unlock rating and forecasts
246 ALECAlector, Inc. Life Sciences 0.40 $209M Unlock rating and forecasts
247 NAGENiagen Bioscience, Inc. Life Sciences 0.67 $204M Neutral +0.20% -0.02% ·
248 RNACCartesian Therapeutics, Inc. Life Sciences 0.23 $199M Unlock rating and forecasts
249 SIONSionna Therapeutics, Inc. Life Sciences 0.02 $198M Unlock rating and forecasts
250 CGENCOMPUGEN LTD Life Sciences 0.42 $196M Neutral -0.11% -0.29% ·
201–250 of 288 Previous Next
Since the previous run

Rating changes

▲ 53▼ 57
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-13) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.